NEW YORK (GenomeWeb) – A Mycobacterium tuberculosis assay launched by Cepheid last week is likely to increase the number of pediatric, extrapulmonary, and HIV co-infected TB cases detected. The new test, which runs on Cepheid's GeneXpert platform, has increased sensitivity compared to the firm's original MTB/RIF test, leading the World Health Organization to draft new guidelines for its use.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.